EU vs US Market Access: Key Differences for Pharma Companies
Written byNeta Kela, PhDFounder & Managing Partner
EU vs US Market Access: Key Differences for Pharma Companies
For biotech and pharma companies preparing to bring a therapy to market, one of the most consequential strategic decisions is how to approach market access across different geographies.
The European Union and the United States represent the two largest pharmaceutical markets globally — but the path to commercial success in each region is fundamentally different.
Understanding these differences early in development is not optional. It is a strategic imperative.
The Regulatory Landscape: One Agency vs Many
United States
In the US, the Food and Drug Administration (FDA) serves as the single regulatory authority for drug approval. Companies submit a single application — whether a New Drug Application (NDA) or Biologics License Application (BLA) — and receive a unified decision.
The FDA also offers several accelerated pathways:
- Fast Track designation
- Breakthrough Therapy designation
- Priority Review
- Accelerated Approval
These pathways can significantly compress approval timelines for therapies addressing serious conditions with unmet medical need.
European Union
In Europe, the European Medicines Agency (EMA) provides a centralized marketing authorization. However, this is only the beginning.
After EMA approval, each EU member state conducts its own Health Technology Assessment (HTA) and pricing and reimbursement negotiations. This means a drug approved by the EMA may take an additional 12 to 24 months — sometimes longer — to become available to patients in individual countries.
Key HTA bodies include:
- NICE (United Kingdom)
- G-BA / IQWiG (Germany)
- HAS (France)
- AIFA (Italy)
- ZIN (Netherlands)
Key takeaway: US approval means market access. EU approval is the starting point for a country-by-country negotiation process.
Pricing and Reimbursement: Free Market vs Regulated
United States
The US operates largely as a free-pricing market. Pharma companies set their own list prices. However, actual net prices are shaped by negotiations with:
- Pharmacy Benefit Managers (PBMs)
- Commercial insurers
- Medicare and Medicaid
The Inflation Reduction Act (IRA) has introduced government price negotiation for select Medicare drugs, marking a significant shift in the US pricing landscape.
Despite these changes, the US still offers the highest price realization globally for innovative therapies.
European Union
EU markets use regulated pricing systems. Most countries employ some combination of:
- External Reference Pricing (ERP): prices are benchmarked against prices in other EU countries
- Internal Reference Pricing: prices are compared to therapeutic alternatives within the same country
- Value-based pricing: price is linked to demonstrated clinical and economic value
This creates a complex pricing interdependency across Europe. The price set in one country can directly impact the achievable price in others.
Launch sequencing becomes critical: companies typically launch first in countries with higher price tolerance (Germany, UK) before expanding to reference-dependent markets.
Key takeaway: In the US, pricing is a commercial negotiation. In the EU, pricing is a regulatory and economic exercise shaped by HTA outcomes and cross-border reference systems.
Payer Engagement and Evidence Requirements
United States
US payers — both commercial and government — focus on:
- Clinical trial data (efficacy and safety)
- Pharmacoeconomic value (cost-effectiveness is considered but less formalized than in EU)
- Formulary positioning and step-therapy protocols
Payer engagement typically intensifies around Phase 3 and launch readiness.
European Union
EU HTA bodies have formal, structured evidence requirements. Companies must submit detailed dossiers demonstrating:
- Comparative effectiveness against standard of care
- Cost-effectiveness (ICER thresholds vary by country)
- Budget impact analysis
- Real-world evidence (increasingly requested post-approval)
The upcoming EU HTA Regulation (effective from 2025 onward) aims to harmonize clinical assessment across member states — though pricing and reimbursement decisions will remain national.
Key takeaway: EU market access demands a more comprehensive evidence package, and payer engagement should begin much earlier — ideally during Phase 2 trial design.
Distribution and Market Structure
United States
The US distribution model is well-established:
- Specialty pharmacy for complex therapies
- Buy-and-bill for physician-administered products
- Direct-to-patient models for certain rare disease therapies
A single distribution strategy can cover the entire market.
European Union
EU distribution varies significantly by country:
- Hospital-based distribution dominates in some markets
- Retail pharmacy in others
- Tender-based procurement in the Nordics and some Eastern European markets
Each market may require a tailored distribution and channel strategy.
Key takeaway: US distribution is relatively uniform. EU distribution requires country-specific planning and local partnerships.
Go-to-Market Timeline: Speed vs Complexity
| Milestone | United States | European Union |
|---|---|---|
| Regulatory approval | 10–12 months (standard) | 12–15 months (centralized) |
| First patient access | At approval | 6–24 months post-approval |
| Full market coverage | Weeks to months | 2–5 years across EU |
| Price negotiations | Commercial (ongoing) | Formal HTA process per country |
EU launches typically lag US launches by 12 to 24 months. For small and mid-size biotech companies, this delay has significant implications for revenue planning, investor expectations, and partnership timing.
Strategic Considerations for Biotech Companies
1. Start EU market access planning during Phase 2
Waiting until Phase 3 results to think about EU HTA requirements is too late. Trial endpoints, comparators, and evidence generation should reflect EU payer expectations from the start.
2. Develop a deliberate launch sequencing strategy
Not all EU markets should be launched simultaneously. Prioritize markets based on price potential, patient population, and reference pricing impact.
3. Align regulatory and commercial teams early
In the US, regulatory approval largely equals market access. In the EU, regulatory and market access are distinct workstreams that must be coordinated.
4. Consider the role of strategic advisory
Navigating cross-border market access requires deep expertise in regulatory systems, pricing dynamics, and payer landscapes across multiple geographies. Engaging experienced advisors early can prevent costly missteps and accelerate time to revenue.
Looking Ahead
The pharmaceutical market access landscape is evolving rapidly on both sides of the Atlantic.
In the US, the Inflation Reduction Act is reshaping pricing dynamics for the first time. In the EU, the new HTA Regulation promises greater harmonization — but implementation challenges remain.
For biotech companies with global ambitions, the companies that invest in integrated, cross-border market access strategy from the earliest stages of development will be the ones best positioned to bring their therapies to patients — and to build sustainable commercial success.
*At PXM, we advise pharma and biotech companies on market access strategy across European and US markets. If you are planning a cross-border launch or evaluating your commercialization approach, get in touch.*
How PXM Helps With This
IND-Enabling Regulatory Strategy
Pre-IND strategy, nonclinical package design, and IND readiness planning.
Biotech Readiness Assessment
A 10 minute diagnostic of your regulatory, CMC, and partnering readiness.
Resources for Biotech Founders
Funding and regulatory bodies, guidance portals, and grant programs in one hub.
Related
Part of Capital, Licensing & M&A. Start from the pillar: For Investors & Pharma, Scout practice, Transact practice
The Delaware Flip: How European Biotechs Win US VC Funding
What a Delaware flip is, when a European biotech should do one, and what US VCs check in diligence. Includes a US-VC readiness checklist.
Biotech M&A Targets in 2026: Where Pharma Is Really Buying
Biotech M&A targets in 2026: oncology and immunology lead, CVRM fades, China licensing surges. Where buyers are spending and the red flags to check.
From UK to Global: A Commercialization Roadmap for British Biotech Companies
The UK is one of the world's strongest life science ecosystems — but for British biotech companies with global ambitions, moving from a UK-centric operation to a commercially successful international business requires deliberate strategy across regulatory, commercial, and partnership dimensions.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.